DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-Based Regimen Switch Strategy to Manage Integrase Inhibitor-Related Weight Gain.

Clin Infect Dis · 2025 · PMC11912975 · PMID 39230668

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a retrospective, longitudinal analysis of medical records, PWH at risk of weight gain and on an INSTI-based regimen showed a trend toward favorable weight and body mass index (BMI) outcomes after switching to a PI-based regimen versus switching to another INSTI-based regimen; differences in outcomes widened over 9 to 12 months post–ARV switch [ 14 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.